ARCT vs KRRO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ARCT exhibits severe financial distress despite a modest insider sentiment score and analyst buy consensus. The Piotroski F-Score of 0/9 signals extreme financial weakness, with no positive indicators in profitability, cash flow, or leverage management. The Altman Z-Score is unavailable, but the company's negative margins, declining revenue, and negative earnings suggest high distress risk. While the stock trades below its 52-week high, its 5-year decline of 87.2% and persistent losses underscore deep operational challenges. The Graham Number and intrinsic value are unavailable, indicating no reliable fundamental floor, and the current price reflects speculative expectations rather than sustainable value.
KRRO exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. While the company maintains a strong liquidity position with a current ratio of 6.90, this is offset by an extreme operating margin of -1229.33% and negative revenue growth of -43.10%. The stock is in a heavy technical downtrend, having lost over 70% of its value in the last six months. Despite a bullish analyst target of $20.00, the deterministic data suggests a high-risk speculative profile with no current path to profitability.
Compare Another Pair
Related Comparisons
ARCT vs KRRO: Head-to-Head Comparison
This page compares Arcturus Therapeutics Holdings Inc. (ARCT) and Korro Bio, Inc. (KRRO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.